New Vaccine-Immunotherapy cocktail shows promise in ovarian cancer trial
NCT ID NCT03029403
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with an experimental vaccine called DPX-Survivac and low-dose chemotherapy (cyclophosphamide) can shrink tumors in people with advanced ovarian, peritoneal, or fallopian tube cancer. The vaccine teaches the immune system to recognize and kill cancer cells, while pembrolizumab removes a brake on the immune system. The trial enrolled 47 participants who had already received platinum-based chemotherapy and whose cancer had progressed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda), DPX-Survivac vaccine, and cyclophosphamide
- What this could lead to
- If it works, this combination could offer a new treatment option that helps control advanced ovarian, peritoneal, or fallopian tube cancer by boosting the immune system to attack cancer cells.
- What could go wrong
- This is a small, early-phase trial (47 participants) with no control group, so results may not apply broadly. The combination may cause side effects like immune-related reactions or infections, and it is not yet proven to be effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Can a Patient's own immune cells be supercharged to fight ovarian cancer?